TG Therapeutics, Inc. $TGTX Stock Holdings Raised by New York State Common Retirement Fund

New York State Common Retirement Fund lifted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 7.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 358,817 shares of the biopharmaceutical company’s stock after purchasing an additional 25,971 shares during the period. New York State Common Retirement Fund owned about 0.23% of TG Therapeutics worth $12,962,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of TGTX. Jump Financial LLC grew its position in shares of TG Therapeutics by 551.8% during the 2nd quarter. Jump Financial LLC now owns 320,022 shares of the biopharmaceutical company’s stock valued at $11,518,000 after buying an additional 270,922 shares during the last quarter. Marex Group plc bought a new position in TG Therapeutics in the second quarter worth about $10,017,000. KLP Kapitalforvaltning AS boosted its stake in TG Therapeutics by 7.7% in the second quarter. KLP Kapitalforvaltning AS now owns 30,800 shares of the biopharmaceutical company’s stock valued at $1,108,000 after acquiring an additional 2,200 shares during the period. Yorktown Management & Research Co Inc acquired a new position in TG Therapeutics in the second quarter valued at approximately $383,000. Finally, Prudential Financial Inc. grew its holdings in shares of TG Therapeutics by 5.5% during the second quarter. Prudential Financial Inc. now owns 189,315 shares of the biopharmaceutical company’s stock valued at $6,813,000 after purchasing an additional 9,925 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently issued reports on TGTX. JPMorgan Chase & Co. cut their price target on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a report on Monday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research report on Monday, December 29th. Wall Street Zen upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, December 14th. Cantor Fitzgerald restated an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. Finally, The Goldman Sachs Group increased their price objective on shares of TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a report on Thursday, January 15th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, TG Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $50.00.

Insider Buying and Selling

In other TG Therapeutics news, Director Yann Echelard sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $32.57, for a total value of $162,850.00. Following the completion of the sale, the director directly owned 223,816 shares in the company, valued at $7,289,687.12. This represents a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.64% of the stock is currently owned by insiders.

TG Therapeutics Stock Down 0.8%

Shares of TG Therapeutics stock opened at $29.18 on Tuesday. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.82 and a quick ratio of 2.89. TG Therapeutics, Inc. has a 1-year low of $25.28 and a 1-year high of $46.48. The business’s fifty day moving average price is $30.68 and its two-hundred day moving average price is $31.94. The company has a market capitalization of $4.63 billion, a P/E ratio of 10.50 and a beta of 1.85.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $2.19. The company had revenue of $161.71 million for the quarter, compared to analyst estimates of $152.12 million. TG Therapeutics had a return on equity of 133.24% and a net margin of 84.13%.The company’s quarterly revenue was up 92.7% compared to the same quarter last year. During the same period last year, the company earned $0.02 earnings per share. As a group, research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.